{"id":749414,"date":"2023-04-20T07:06:59","date_gmt":"2023-04-20T11:06:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\/"},"modified":"2023-04-20T07:06:59","modified_gmt":"2023-04-20T11:06:59","slug":"tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\/","title":{"rendered":"Tiziana Life Sciences to File Alzheimer\u2019s IND for Intranasal Foralumab in Q2 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">\n          <strong>Application for $3M of non-dilutive funding for Phase 2a Alzheimer\u2019s trial will be submitted in Q2 2023<\/strong>\n        <\/li>\n<li style=\"text-align:left\">\n          <strong>Tiziana guided by FDA Type \u201cB\u201d meeting comments on its scheduled Q2 2023 intranasal foralumab Alzheimer\u2019s IND filing<\/strong>\n        <\/li>\n<li style=\"text-align:left\">\n          <strong>Alzheimer\u2019s patients will be administered 3-months of intranasal foralumab to study effects on neuroinflammation caused microglia activation<\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"left\">NEW YORK, April  20, 2023  (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd.\u00a0(Nasdaq: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ro_JtVcj9B2DZBhPuxYSvaeBwpPYyf_dfDA1LGthRR7-wDi-N1arZ9AJA0-DStJ02kZ8a87i_XOEigyK4jE0SIDRsC7Fd9NScoRs_loAXq2txInxrSOy9AoLS1E-2hy9\" rel=\"nofollow noopener\" target=\"_blank\">TLSA<\/a>) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced its plan to submit an IND for intranasal foralumab in patients with mild to moderate Alzheimer\u2019s Disease in Q2 2023.<\/p>\n<p align=\"left\">\u201cFollowing the FDA feedback from our protocol and development plans from the August 2022 type \u201cB\u201d Pre-IND meeting, Tiziana plans submit its intranasal foralumab protocol and IND for mild to moderate Alzheimer\u2019s disease in Q2 2023,\u201d stated Gabriele Cerrone, Executive Chairman, Founder and interim Chief Executive Officer of Tiziana. \u201cTiziana is also seeking $3,000,000 in non-dilutive funding from a prestigious Alzheimer\u2019s foundation to support the Phase 2a trial. It is my expectation that this funding application will be submitted Q2 2023 with a response expected Q3 2023.\u201d<\/p>\n<p align=\"left\">\u201cThere are no FDA approved treatments for Alzheimer\u2019s disease specific to the neuroinflammation caused microglia activation triggered by amyloid beta plaque,\u201d commented Matthew W. Davis, M.D., RPh, Chief Medical Officer of Tiziana. \u201cWe plan to study 3-months administration of intranasal foralumab in Alzheimer\u2019s disease patients to see if neuroinflammatory activated microglia will return to the baseline homeostatic state.\u201d\u00a0\u00a0<\/p>\n<p align=\"left\">\n        <strong>About Foralumab<\/strong>\n      <\/p>\n<p align=\"left\">Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials are expected to start in the third quarter of 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseases.<sup>1<\/sup><\/p>\n<p align=\"left\">\n        <strong>About\u00a0Tiziana Life Sciences<\/strong>\n      <\/p>\n<p align=\"left\">Tiziana Life Sciences\u00a0is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana\u2019s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery.\u00a0 Tiziana\u2019s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana\u2019s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.<\/p>\n<p align=\"left\">For further inquiries:<\/p>\n<p align=\"left\">\n        <strong>Tiziana Life Sciences Ltd<\/strong>\n      <\/p>\n<p align=\"left\">Paul Spencer, Business Development and Investor Relations <br \/>+44 (0) 207 495 2379<br \/>email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ys4PIlIdEJQ9mw7wtpzY6tiCaHy2DXt6-rhGp8SrMuupgbfCqCe7PzWG277O-s9VeZikEvrTIigyLrKn3FGIW0tL_jJfNqfD71JVuNfJqCF59P0FsenQAxXSLCaVwwV-gV2AGWqR31ovtEiPaPRu1ZITP3jlkCjnJK0pOfH9dd5SMR6XMqn84CmNl8qJNXx91lt0aDSn1ketjjmERqd9USqBxLIqRERyCkbI81t19oOgAnwkeIjBe_XpANW6Tya-9_zXeL7PvEdWwlAtA-79I5q_34yWj__Uz79wDRptB-l4m1JPQKHYo480qFAEEPL_kr98cSjIiOlkCtu0WEI1pgA42rhGHD1C03oEQAMcm_K8w_bLLFm-LNRdVj3emMugfeNxq_ctaI1wPH95bbSKSaCvUAPx2aaIn8VuK-00zVJXTFrPxS5-2P5ocOadOSOOqbTNfdbASfrmqzeAObpfK5cEMfbINWbs3FfAQ19hXqkf8YH2YtN41SngGaP8LxDKbC7fvxLcmW8Gfy2aZfYZHw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>info@tizianalifesciences.com<\/u><\/a><\/p>\n<p align=\"left\">\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Irina Koffler<br \/>LifeSci Advisors, LLC<br \/>+1 646 970 4681<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zXshz_lAzm5dwfukFnYNHLHULMEJJiMa8KFqMccmUWO-t9h4j1kRyRqX1hMCuJseWKE7R7DWtUhCSXQ0yQ1n0-GWxfTEUNjP6cXBMQSAfYbPjmJRux9Xek2CnPe7Q9D8ymGXIQx4tQWMmB842Te0n-8tiJ2Q_hBG2Qqd0Udh3mQQCcorNW_DJQZ6LpLNwpaiGtkoZVv5gZOOFA5z-fnLSie0TyCL2Dw3Ag6SUYHBrPrXj9_mdjnorx5dyAJq_Y0sz5ZrBESCzoDGN2ZopRWCYsD1A0OSPpZXOk2nOIVOAZ1wX1nOKru6Yi8UQFPVXgeQhVdaNVdGT6F_8jxa02pkigdUlCy2FcQZ5g7G7dujUTZRYTWMcDKq2x4w2YGUXE1uYdGorIZ2KWDNviyAfZHuOWGKxhdiMxBE18CwbQ-psoO5Tj8U52x2A655RASSMtgVdax6yDKQUC4FPoQHqwMGmIEGNYq1LMsHqwqOX-OyeM76RGoYs7MMhyVLfh08TM_BBfuQ9o8fGK7AAi5IXkQzSw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>ikoffler@lifesciadvisors.com<\/u><\/a><\/p>\n<p align=\"left\">____________________<br \/><sup>1<\/sup>\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jjTJAH7jP61nwtPyJJOkW07F6lRTfKJ_dfUAMG9_7sMm6GVj1dHBfkhpRfKztkE2D4EHeAvdcgM3rKqwQZuTD-EIcYNYpie6jk3_qp_Mv-UElIu0n_k1y3pg84dgaXibK8uno8MGZ57aEwbxk7yZyxDj-0vv0lmv0Ezx0uBbays=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.pnas.org\/doi\/10.1073\/pnas.2220272120<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTQ0NyM1NTM2MDg4IzIxMjM4ODU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDUwMDBjNWUtNTdlMi00MmUyLThkYzktNmY5OTYyNzdlNDhhLTExMzU0NTY=\/tiny\/Tiziana-Life-Sciences-Plc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Application for $3M of non-dilutive funding for Phase 2a Alzheimer\u2019s trial will be submitted in Q2 2023 Tiziana guided by FDA Type \u201cB\u201d meeting comments on its scheduled Q2 2023 intranasal foralumab Alzheimer\u2019s IND filing Alzheimer\u2019s patients will be administered 3-months of intranasal foralumab to study effects on neuroinflammation caused microglia activation NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd.\u00a0(Nasdaq: TLSA) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced its plan to submit an IND for intranasal foralumab in patients with mild to moderate Alzheimer\u2019s Disease in Q2 2023. \u201cFollowing the FDA feedback from our protocol and development plans from the August 2022 type \u201cB\u201d &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Tiziana Life Sciences to File Alzheimer\u2019s IND for Intranasal Foralumab in Q2 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-749414","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tiziana Life Sciences to File Alzheimer\u2019s IND for Intranasal Foralumab in Q2 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tiziana Life Sciences to File Alzheimer\u2019s IND for Intranasal Foralumab in Q2 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Application for $3M of non-dilutive funding for Phase 2a Alzheimer\u2019s trial will be submitted in Q2 2023 Tiziana guided by FDA Type \u201cB\u201d meeting comments on its scheduled Q2 2023 intranasal foralumab Alzheimer\u2019s IND filing Alzheimer\u2019s patients will be administered 3-months of intranasal foralumab to study effects on neuroinflammation caused microglia activation NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd.\u00a0(Nasdaq: TLSA) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced its plan to submit an IND for intranasal foralumab in patients with mild to moderate Alzheimer\u2019s Disease in Q2 2023. \u201cFollowing the FDA feedback from our protocol and development plans from the August 2022 type \u201cB\u201d &hellip; Continue reading &quot;Tiziana Life Sciences to File Alzheimer\u2019s IND for Intranasal Foralumab in Q2 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-20T11:06:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTQ0NyM1NTM2MDg4IzIxMjM4ODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tiziana Life Sciences to File Alzheimer\u2019s IND for Intranasal Foralumab in Q2 2023\",\"datePublished\":\"2023-04-20T11:06:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\\\/\"},\"wordCount\":496,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMTQ0NyM1NTM2MDg4IzIxMjM4ODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\\\/\",\"name\":\"Tiziana Life Sciences to File Alzheimer\u2019s IND for Intranasal Foralumab in Q2 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMTQ0NyM1NTM2MDg4IzIxMjM4ODU=\",\"datePublished\":\"2023-04-20T11:06:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMTQ0NyM1NTM2MDg4IzIxMjM4ODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMTQ0NyM1NTM2MDg4IzIxMjM4ODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tiziana Life Sciences to File Alzheimer\u2019s IND for Intranasal Foralumab in Q2 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tiziana Life Sciences to File Alzheimer\u2019s IND for Intranasal Foralumab in Q2 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\/","og_locale":"en_US","og_type":"article","og_title":"Tiziana Life Sciences to File Alzheimer\u2019s IND for Intranasal Foralumab in Q2 2023 - Market Newsdesk","og_description":"Application for $3M of non-dilutive funding for Phase 2a Alzheimer\u2019s trial will be submitted in Q2 2023 Tiziana guided by FDA Type \u201cB\u201d meeting comments on its scheduled Q2 2023 intranasal foralumab Alzheimer\u2019s IND filing Alzheimer\u2019s patients will be administered 3-months of intranasal foralumab to study effects on neuroinflammation caused microglia activation NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd.\u00a0(Nasdaq: TLSA) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced its plan to submit an IND for intranasal foralumab in patients with mild to moderate Alzheimer\u2019s Disease in Q2 2023. \u201cFollowing the FDA feedback from our protocol and development plans from the August 2022 type \u201cB\u201d &hellip; Continue reading \"Tiziana Life Sciences to File Alzheimer\u2019s IND for Intranasal Foralumab in Q2 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-20T11:06:59+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTQ0NyM1NTM2MDg4IzIxMjM4ODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tiziana Life Sciences to File Alzheimer\u2019s IND for Intranasal Foralumab in Q2 2023","datePublished":"2023-04-20T11:06:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\/"},"wordCount":496,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTQ0NyM1NTM2MDg4IzIxMjM4ODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\/","name":"Tiziana Life Sciences to File Alzheimer\u2019s IND for Intranasal Foralumab in Q2 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTQ0NyM1NTM2MDg4IzIxMjM4ODU=","datePublished":"2023-04-20T11:06:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTQ0NyM1NTM2MDg4IzIxMjM4ODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTQ0NyM1NTM2MDg4IzIxMjM4ODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-file-alzheimers-ind-for-intranasal-foralumab-in-q2-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tiziana Life Sciences to File Alzheimer\u2019s IND for Intranasal Foralumab in Q2 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/749414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=749414"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/749414\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=749414"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=749414"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=749414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}